|
| Study | The primary outcomes | The secondary outcomes | The safety outcomes |
|
| Antoniucci et al. [27] | Composite of death from any cause, reinfarction, TVR, and stroke within one month | ST-segment reduction; postprocedural cTFC; infarct size at one month; all-cause death, reinfarction, a composite of death and reinfarction, TVR at 6 months | — |
| Brener et al. [22] | Death, reinfarction, or any TVR at 6 months | Early death, reinfarction, or urgent TVR | Bleeding |
| Ernst et al. [23] | Recurrent MI | — | Bleeding |
| Mehilli et al. [24] | Infarct size measured by SPECT | All-cause death, recurrent MI, stroke, urgent TVR, the in-hospital incidence of bleeding complications | Bleeding |
| Montalescot et al. [4] | composite of death, reinfarction, or urgent TVR | composite of death, reinfarction, or any TVR at 30 days and 6 months | Bleeding |
| Neumann et al. [25] | The differences in papaverine-induced coronary flow velocity and in wall motion index between the initial and 14-day follow-up | The adverse cardiac events (death, nonlethal reinfarction, and TVR) at 30 days | — |
| Neumann et al. [3] | Late loss; composite of death, recurrent MI, and TVR | Nonfatal death, recurrent MI, and TVR | — |
| Petronio et al. [28] | Prevalence of 6-month left ventricular remodeling | Prevalence of angiographic no-reflow during angioplasty; the final cTFC; the percent change in LVEDV at 6 months | — |
| Tcheng et al. [26] | Composite of death, reinfarction, urgent repeat TVR, or disabling stroke at 30 days/12 months | — | Bleeding |
| Zorman et al. [29] | Composite of death, heart failure, and/or urgent TVR | — | — |
|
